Physician profile
Dawna C Hilton
NPI 1932443694
$5,778.33
in general payments reported to CMS, 2019-2025
31 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2022: $642 · 2023: $1,133 · 2024: $1,415 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $821.05 | 2023-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $442.82 | 2023-2025 | Breztri, Farxiga |
| Cvrx, INC. | $414.21 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $361.91 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $352.76 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.06 | 2021-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $341.50 | 2024-2025 | Assure Wcd |
| Pfizer INC. | $259.79 | 2022-2025 | |
| Amgen INC. | $246.01 | 2021-2025 | Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $233.66 | 2021-2025 | Gvoke Hypopen |
| Medtronic, INC. | $225.16 | 2022-2025 | Symplicity G3, Micra, Turbohawk |
| Merck Sharp & Dohme LLC | $137.54 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $135.65 | 2023-2025 | |
| Abiomed | $132.97 | 2025 | |
| Esperion Therapeutics, INC. | $125.80 | 2021-2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $121.83 | 2025 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $120.72 | 2024 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $117.99 | 2025 | Arexvy |
| Abbott Laboratories | $116.37 | 2022-2025 | Aveir |
| Neurocrine Biosciences, INC. | $108.82 | 2023 | Ingrezza |
| Eisai INC. | $103.19 | 2025 | |
| Atricure, INC. | $102.55 | 2023-2025 | Synergy Ablation System |
| Biogen, INC. | $82.61 | 2022 | |
| Boston Scientific Corporation | $59.57 | 2023-2024 | Varithena Administration Pack, Wavewriter Alpha Prime 16 |
| Scpharmaceuticals INC. | $37.02 | 2023 | |
| Vital Connect, INC | $30.35 | 2023 | Vitalpatch Rtm |
| Bayer Healthcare Pharmaceuticals INC. | $24.66 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.83 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $21.36 | 2025 | Edarbi |
| Irhythm Technologies, INC. | $16.76 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawna Hilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.